E3 ligase Ligand 1 |
| Catalog No.GC32711 |
El ligando 1 de ligasa E3 (clorhidrato de ligando 2 de VHL) es el ligando VHL basado en (S,R,S)-AHPC que se utiliza en el reclutamiento de la proteÍna von Hippel-Lindau (VHL). El ligando 1 de ligasa E3 se puede utilizar para sintetizar ARV-771, un degradador BET PROTAC basado en ligasa E3 de von Hippel-Landau (VHL). ARV-771 degrada potentemente la proteÍna BET en células de cÁncer de prÓstata resistente a la castraciÓn (CRPC) con un DC50 <1 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1948273-03-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
E3 ligase Ligand 1 is a Ligand for E3 Ligase extracted from patent WO/2017/030814A1 compound example 202, used in PROTAC technology.
E3 ligase Ligand 1 is a VHL E3 ligase-binding ligand[1]. E3 ligase Ligand 1 is used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC. ARV-771, a small-molecule pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technology, demonstrates dramatically improved efficacy in cellular models of castration-resistant prostate cancer (CRPC) as compared with BET inhibition[2].
[1]. WO/2017/030814A1 [2]. Kanak R, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America (2016), 113(26), 7124-7129
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *